153 related articles for article (PubMed ID: 11422050)
1. Intralesional rituximab for cutaneous B-cell lymphoma.
Paul T; Radny P; Kröber SM; Paul A; Blaheta HJ; Garbe C
Br J Dermatol; 2001 Jun; 144(6):1239-43. PubMed ID: 11422050
[TBL] [Abstract][Full Text] [Related]
2. Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases.
Kerl K; Prins C; Saurat JH; French LE
Br J Dermatol; 2006 Dec; 155(6):1197-200. PubMed ID: 17107389
[TBL] [Abstract][Full Text] [Related]
3. CD20-negative relapse of cutaneous B-cell lymphoma after anti-CD20 monoclonal antibody therapy.
Massengale WT; McBurney E; Gurtler J
J Am Acad Dermatol; 2002 Mar; 46(3):441-3. PubMed ID: 11862185
[TBL] [Abstract][Full Text] [Related]
4. Systemic therapy of primary cutaneous B-cell lymphoma, marginal zone type, with rituximab, a chimeric anti-CD20 monoclonal antibody.
Soda R; Costanzo A; Cantonetti M; Orlandi A; Bianchi L; Chimenti S
Acta Derm Venereol; 2001; 81(3):207-8. PubMed ID: 11558880
[No Abstract] [Full Text] [Related]
5. Treatment of primary cutaneous B-cell lymphoma with rituximab.
Fink-Puches R; Wolf IH; Zalaudek I; Kerl H; Cerroni L
J Am Acad Dermatol; 2005 May; 52(5):847-53. PubMed ID: 15858476
[TBL] [Abstract][Full Text] [Related]
6. Intralesional therapy with anti-CD20 monoclonal antibody rituximab in primary cutaneous B-cell lymphoma.
Heinzerling L; Dummer R; Kempf W; Schmid MH; Burg G
Arch Dermatol; 2000 Mar; 136(3):374-8. PubMed ID: 10724200
[TBL] [Abstract][Full Text] [Related]
7. Intralesional therapy with anti-CD20 monoclonal antibody rituximab: local and systemic efficacy in primary cutaneous B-cell lymphoma.
Roguedas AM; Watier H; Paintaud G; de Muret A; Vaillant L; Machet L
Br J Dermatol; 2005 Mar; 152(3):541-4. PubMed ID: 15787825
[TBL] [Abstract][Full Text] [Related]
8. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
Gellrich S; Muche JM; Wilks A; Jasch KC; Voit C; Fischer T; Audring H; Sterry W
Br J Dermatol; 2005 Jul; 153(1):167-73. PubMed ID: 16029344
[TBL] [Abstract][Full Text] [Related]
9. Rituximab in cutaneous B-cell lymphoma: a report of two cases.
Sabroe RA; Child FJ; Woolford AJ; Spittle MF; Russell-Jones R
Br J Dermatol; 2000 Jul; 143(1):157-61. PubMed ID: 10886152
[TBL] [Abstract][Full Text] [Related]
10. Systemic therapy with cyclophosphamide and anti-CD20 antibody (rituximab) in relapsed primary cutaneous B-cell lymphoma: a report of 7 cases.
Fierro MT; Savoia P; Quaglino P; Novelli M; Barberis M; Bernengo MG
J Am Acad Dermatol; 2003 Aug; 49(2):281-7. PubMed ID: 12894078
[TBL] [Abstract][Full Text] [Related]
11. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group.
Tobinai K; Kobayashi Y; Narabayashi M; Ogura M; Kagami Y; Morishima Y; Ohtsu T; Igarashi T; Sasaki Y; Kinoshita T; Murate T
Ann Oncol; 1998 May; 9(5):527-34. PubMed ID: 9653494
[TBL] [Abstract][Full Text] [Related]
12. Primary cutaneous large B-cell lymphoma of the legs: a distinct clinical pathologic entity treated with CD20 monoclonal antibody (rituximab).
Aboulafia DM
Am J Clin Oncol; 2001 Jun; 24(3):237-40. PubMed ID: 11404492
[TBL] [Abstract][Full Text] [Related]
13. Complete remission of a primary cutaneous B-cell lymphoma of the lower leg by first-line monotherapy with the CD20-antibody rituximab.
Bonnekoh B; Schulz M; Franke I; Gollnick H
J Cancer Res Clin Oncol; 2002 Mar; 128(3):161-6. PubMed ID: 11935303
[TBL] [Abstract][Full Text] [Related]
14. Rituximab monotherapy for primary cutaneous B-cell lymphoma: response and follow-up in 16 patients.
Valencak J; Weihsengruber F; Rappersberger K; Trautinger F; Chott A; Streubel B; Muellauer L; Der-Petrossian M; Jonak C; Binder M; Raderer M
Ann Oncol; 2009 Feb; 20(2):326-30. PubMed ID: 18836086
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous B-cell lymphoma responds to rituximab: a report of five cases and a review of the literature.
Gitelson E; Al-Saleem T; Millenson M; Lessin S; Smith MR
Leuk Lymphoma; 2006 Sep; 47(9):1902-7. PubMed ID: 17065004
[TBL] [Abstract][Full Text] [Related]
16. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA
J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122
[TBL] [Abstract][Full Text] [Related]
17. Anti-CD20 monoclonal antibody (Rituximab) for therapy of mediastinal CD20-positive large B-cell non-Hodgkin lymphoma with a local tumor extension into the lung of a 10-year-old girl.
Culić S; Culić V; Armanda V; Kuljis D; Pesutić-Pisac V; Janković S
Pediatr Hematol Oncol; 2003 Jun; 20(4):339-44. PubMed ID: 12746167
[TBL] [Abstract][Full Text] [Related]
18. Favorable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab.
Kyrtsonis MC; Siakantaris MP; Kalpadakis C; Dimopoulou MN; Vassilakopoulos TP; Kontopidou FN; Antoniou C; Korkolopoulou P; Panayiotidis P; Pangalis GA
Eur J Haematol; 2006 Oct; 77(4):300-3. PubMed ID: 16856917
[TBL] [Abstract][Full Text] [Related]
19. [Low-grade cutaneous B-cell lymphoma: Failure of intralesional rituximab (Mabthera)].
Abasq C; Duval-Modeste AB; Courville P; Joly P
Ann Dermatol Venereol; 2008; 135(6-7):509-11. PubMed ID: 18598807
[No Abstract] [Full Text] [Related]
20. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.
Davis TA; Grillo-López AJ; White CA; McLaughlin P; Czuczman MS; Link BK; Maloney DG; Weaver RL; Rosenberg J; Levy R
J Clin Oncol; 2000 Sep; 18(17):3135-43. PubMed ID: 10963642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
